About the Book
Most of the familiar headache drugs are used to stop a headache attack that is already in progress, or about to begin. However, there is now a growing body of research aimed at developing medications that can be taken on a regular basis to prevent headcahes from starting. These drugs will be targetted at patients whose headaches are frequent or who get their headaches at predicatble times. This book reviews the potential for prophylactic treatment of headache. It
provides most of the existing evidence in the field of pharmaco-prophylaxis of migraine and other chronic headaches and may thus, serve as a platform for new initiatives in the field. The book reviews
the research into the pharmacological mechanisms involved, the classes of drugs in development and the clinical trials methodology. The editors have gathered together the leading international experts to produce a book that will appeal neurologists caring for headache patients, researchers in the field and those based in the pharmaceutical industry.
Table of Contents:
Section I - Methodology of prophylactic trials
1: Peter J Goadsby: Principles of preventive pharmacotherapy in primary headache
2: Henry J McQuay: Methodology and implementation of systematic reviews
3: Doris Irene Stenver: Adverse events, equally important as efficacy as an outcome parameter?
4: Peer Tfelt-Hansen: Methodology of prophylactic trials: discussion summary
Section II - Prophylactic drugs I
5: Peer Tfelt-Hansen: Key issues in the methodology of prophylactic migraine trials
6: M Lanteri-Minet, H Aalchaar, G Besson, F Bille-Turc, F Brudon, A Donnet, J Valance and JL Gastaut: Migraine prophylaxis: a pharmacoepidemiological study of practices used by general practitioners and neurologists in France
7: W Hester Visser, William Malbecq, Kim Strohmaier, Christopher Lines and Scott A Reines: Preventive treatment of migraine headache with rofecoxib
8: Achim Frese, Katrin Frese, Sonja Schwaag, Alexandra Rahmann, Ingo-W Husstedt and Stefan Evers: Prophylactic treatment and course of the disease in headache associated with sexual activity
9: Stephen D Silberstein: Propylactic drugs I: discussion summary
Section III - Prophylactic drugs II
10: Hans-Christoph Diener and Volker Limmroth: Prevention of migraine: betablockers and amine agonists: efficacy
11: Stephen D Silberstein: Antiepileptic drugs in migraine prevention
12: H Steve White: Mechanism(s) of action of the antiepileptic drugs Valproic Acid, Gabapentin, and Topiramate: implications for the prophylactic management of migraine
13: J Pascual, M Sanchez del Rio, V Mateos, JM Lainez, J Hernandez-Gallego, R Leira and MD Jimenez: Experience with topiramate in patients with refractory migraine
14: Reto M Agosti and Sonja Eugster: Topiramate in a selective group of therapy refractory headache patients
15: Jean Schoenen: Prophylactic drugs II: discussion summary
Section IV - Prophylactic Drugs III
16: Lars Bendtsen: Efficacy of antidepressants in headache prophylaxis
17: Elliott Richelson: Antidepressants: mechanisms of action
18: Jean Schoenen, Laura Di Clemente and Gianluca Coppola: Other prophylactic anti-migraine agents: riboflavin feverfew, magnesium, botulinum toxin and calcium antagonists
19: Isin Baral Kulaksizoglu, Sibel Cakir and Mustafa Ertas: Treatment of chronic tension type headache with mirtazapine
20: Stewart J Tepper, Marcelo E Bigal, Fred D Sheftell and Alan Rapoport: Botulinum toxin type A in the treatment of refractory headache
21: Sonja Schwaag, Alexandra Rahmann, Achim Frese, Ingo-W Husstedt, Juliane Vollmer-Haase and Stefan Evers: Botulinum toxin A in the prophylaxis of migraine - a double-blind, placebo-controlled, randomised study comparing frontal and cervical injection
22: Stephen Silberstein, M Alan Stiles, Cheryl Gebeline-Myers and Kathleen Coughlin Bradley: Description of a prospective, multicenter observational study of headache treatment with Botulinum toxin type A: the program to assess treatment strategies (PATS) registry
23: M Cui and KR Aoki: Mechanisms of the antinociceptive effect of subcutaneous BOTOX: inhibition of peripheral and central nociceptive processing
24: Gabriella Coloprisco, Sergio De Filippis, Pier Giorgio Santi, Guiseppe Fiore, Anna Rodio and Paolo Martelletti: Survey on expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment
25: Yoko Hibi, Hisaka Igarashi, Fumihiko Sakai: Prophylactic treatment of migraine with lomerizine hydrochloride
26: Peter J Goadsby: Prophylactic drugs III: discussion summary
Section V - New Targets I
27: Sally Bolton and Celestine O'Shaughnessy: Antagonising peripheral sensitisation in migraine
28: RG Hill, MJ Cumberbatch and DJ Williamson: New possibilities for antimigraine therapy via 5-HT receptors?
29: B Schaerlinger, P Hickel, N Etienne and L Maroteaux: Dihydroergotamine interaction with 5-HT2 receptors and its relevance to migraine
30: Lars Jacob Stovner, Erling Tronvik, Harald Schrader, Grethe Helde, Trond Sand and Gunnar Bovim: Migraine prophylaxis with drugs influencing the angiotensin system
31: Alan M Rapoport, Marcelo E Bigal, Stewart J Tepper, Fred D Sheftell: Naratriptan in the preventive treatment of refractory chronic migraine
32: A Pradalier, M Lanteri-Minet, Ch Lucas and G Geraud: PROMISE study (PROphylaxis of MIgraine with SEglor)
33: M Hamon, S Bourgoin and L Lanfumey: Serotinin receptors and migraine prophylaxis - the case of dihydroergotamine
34: Richard Peatfeld: What is the mechanism of action of ACE inhibitors in migraine prophylaxis?
35: Dominique Valade: Triptans with methysergide
36: Jes Olesen: New Targets I: discussion summary
Section VI - new targets II
37: Paul JLM Strijbos and Andrew A Parsons: Nitric oxide and its signalling pathways: a rich source of potential targets for migraine therapy
38: Henri Doods: Calcitonin gene related peptide and migraine
39: Christina Kruuse and Joseph A Beavo: Phosphodiesterases, cyclic nucleotides, and their role in migraine
40: Stefan Evers, Achim Frese, Sonja Schwaag, Reiner Luttmann and Ingo-W Husstedt: The prostaglandin-E1-analog misoprostol in the prophylactic treatment of refractory cluster headache and trigeminal neuralgia
41: Ray Hill: New targets II: discussion summary
